Scientists from the National Research University Higher School of Economics and the National Center for Medical Research Radiology have developed a three-dimensional model of prostate cancer in the laboratory. Researchers have already tested one of the anticancer drugs on the model. socialbites.ca was informed about this by the Higher School of Economics of the National Research University.
Prostate cancer is a malignant, slowly progressive disease originating from the epithelium of the prostate gland. The disease is dangerous because it can remain symptom-free for long periods of time. Some forms develop extremely quickly and are fatal. Prostate cancer is the second most common and fifth most lethal cancer in men in the world.
The disease is treated with hormone therapy, chemotherapy, immunotherapy, radiation therapy and targeted therapy.
In recent years, studies with organoids (three-dimensional cell cultures made from tumors) have become widespread. With their help, you can predict the effectiveness of medications and the patient’s reaction to them. Researchers from the Higher School of Economics grew organoids from prostate tumors and tested whether the drug docetaxel could reduce the activity of cancer cells.
It turned out that the drug practically does not reduce the viability of tumor cells. Sergei Nikulin, Associate Professor of the Faculty of Biology and Biotechnology of the Higher School of Economics at the National Research University, noted that in the future, this testing method will allow us to avoid prescribing ineffective drugs and focus on finding suitable alternative treatment regimens. for the patient.
The researchers also hope that in the future the growth process of organoids will be faster and the resulting samples will be more productive.
Previous scientists developed A medication for cancer-related fatigue.
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.